Get started
Author

Ella C Troy

Results of a phase I trial with Haploidentical mbIL ‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML
2024 · Stefan O. Ciurea, Piyanuch Kongtim, et al. · American Journal of Hematology · 35
PDF
CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies
2024 · Ella Troy, Joseph Caporale, et al. · Blood Neoplasia · 13
CD38 KO/CD38-CAR Human Primary Natural Killer Cells Enhance Cytotoxicity Against CD38-Expressing Primary Lymphoma, Leukemia, and Myeloma
2023 · Ella C Troy, Yasemin Sezgin, et al. · Blood · 8
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2021 · Sumithira Vasu, Nidhi Sharma, et al. · Blood · 7
SAR445419 Off-the-Shelf Natural Killer Cells Are Safe and Show Efficacy Signal in Relapsed/Refractory Acute Myeloid Leukemia.
2024 · Sumithira Vasu, Nicole Szuminski, et al. · Transplantation and Cellular Therapy · 2
IL-15 signaling during a critical NK cell developmental window subverts maturation and KIR acquisition
2026 · Michael A. Ruesch, Noah T. Koenigs, et al. · Cell Reports
Expanded NK and fratricide-resistant CD70 CAR-NK cells are potent against patient-derived glioblastoma cells in vitro and in vivo
2026 · Misaal Mehboob, Matthew Rätsep, et al. · Cancer Immunology Immunotherapy
Identification of elements determining KIR gene demethylation at the CD56-bright stage of NK cell development
2026 · Hongchuan Li, Noah T. Koenigs, et al. · iScience
PDF
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Third-Party Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2022 · Sumithira Vasu, Nidhi Sharma, et al. · Transplantation and Cellular Therapy
Works count: 9
Citation count: 65
H-index: 4
I10-index: 2
Year
Topic
Type